The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Two new composition of matter patents granted in the US and Europe <li /> Patents provide protection relating to lead compound S-pindol ...

MicroStrategy is changing its name to reflect its transformation from strictly a software firm to the self-described "world's ...

Guangdong Hongshi Laser Technology Co., Ltd. (HSG Laser) has failed to complete its initial public offering (IPO), marking a ...

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Welcome to the latest edition of “Quantum Leap” where The Fly decodes news and activity in the quantum computing space. Maximize Your ...

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

In the world of luxury fashion, few trademarks are as iconic and instantly recognizable as the red soles of Christian ...

High Court dismisses Halozyme's appeal over SPC applications for medicinal products involving recombinant human hyaluronidase ...

AI policies and priorities have recently become a highly contested regulatory topic in the US, with President Donald Trump’s ...